Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.
Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
Pre vs Post Block in Total Knee Arthroplasty (TKA)
- Conditions
- Knee OsteoarthritisArthroplasty ComplicationsPostoperative Pain
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 84
- Registration Number
- NCT05974501
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Multimodal Pain Package vs. Regular Formulation for Pain Management in Ambulatory Spinal Surgery
- Conditions
- Spinal Disorder
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 100
- Registration Number
- NCT05965492
- Locations
- 🇺🇸
university of Miami, Miami, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
Role of Pentoxifylline and Celecoxib in Parkinsonism
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Mostafa Bahaa
- Target Recruit Count
- 80
- Registration Number
- NCT05962957
- Locations
- 🇪🇬
Faculty of Medicine, Mansoura University, Mansoura, Egypt
Chinese Spondyloarthritis Inception Cohort (CESPIC)
- Conditions
- Crohn Disease (CD)Ulcerative Colitis (UC)Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA)Acute Anterior Uveitis (AAU)Reactive Arthritis (ReA)Non-radiographic Axial Spondyloarthritis (Nr-axSpA)Axial Psoriatic Arthritis (axPsA)
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Southwest Hospital, China
- Target Recruit Count
- 1000
- Registration Number
- NCT05960864
Efficacy and Safety of SKCPT in Patients With Knee Osteoarthritis: Phase III Clinical Trial
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Target Recruit Count
- 278
- Registration Number
- NCT05930080
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
How to Reduce Pain in Patients Undergoing Office Hysteroscopy.
- Conditions
- Pain
- Interventions
- First Posted Date
- 2023-06-20
- Last Posted Date
- 2023-06-20
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 180
- Registration Number
- NCT05911126
Effectiveness of Yunnan Baiyao in Improving Fracture Pain
- Conditions
- Distal Radius Fracture
- Interventions
- Drug: Yunnan Baiyao
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 58
- Registration Number
- NCT05765747
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8Unresectable Triple-Negative Breast CarcinomaMetastatic Triple-Negative Breast Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: BiopsyProcedure: Computed TomographyBiological: Interferon Alpha-2Procedure: Magnetic Resonance Imaging
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT05756166
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Serplulimab Combined with CAPEOX + Celecoxib As Neoadjuvant Treatment for Locally Advanced Rectal Cancer
- Conditions
- PMMRMSSMSI-LLocally Advanced Rectal Carcinoma
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 50
- Registration Number
- NCT05731726
- Locations
- 🇨🇳
Second Affiliated Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China
INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder
- Conditions
- Major Depressive DisorderInflammation
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Universiteit Antwerpen
- Target Recruit Count
- 240
- Registration Number
- NCT05644301
- Locations
- 🇧🇪
UPC Duffel, Duffel, Antwerpen, Belgium
🇧🇪UZ Brussel, Brussels, Belgium
🇧🇪Katholiek Universiteit Leuven Campus Kortenberg, Leuven, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.